Search

Your search keyword '"Jhaveri, Ravi"' showing total 702 results
Start Over Author "Jhaveri, Ravi"
702 results on '"Jhaveri, Ravi"'

157. Elimination Means Everyone: Targeting Hepatitis C in Infants and Pregnant Patients.

Author

Jhaveri, Ravi

Subjects
*HEPATITIS C prevention, *DISEASE eradication, *SERIAL publications, *HEPATITIS C, *VERTICAL transmission (Communicable diseases)
Abstract

The article states that Hepatitis C virus (HCV) elimination efforts have primarily centered on amplifying screening and therapy among adults across diverse settings, with limited inclusion of subsets such as expectant mothers and minors. It focuses on research on testing timelines for infants exposed to HCV and the effectiveness of broad treatment strategies considering the higher rates of random clearance in young children.

Published
2023
Full Text
View/download PDF

165. Receiver operating characteristic curves and confidence bands for support vector machines.

Author

Luckett, Daniel J., Laber, Eric B., El‐Kamary, Samer S., Fan, Cheng, Jhaveri, Ravi, Perou, Charles M., Shebl, Fatma M., and Kosorok, Michael R.

Subjects
RECEIVER operating characteristic curves, SUPPORT vector machines, HIGH-dimensional model representation, CONFIDENCE
Abstract

Many problems that appear in biomedical decision‐making, such as diagnosing disease and predicting response to treatment, can be expressed as binary classification problems. The support vector machine (SVM) is a popular classification technique that is robust to model misspecification and effectively handles high‐dimensional data. The relative costs of false positives and false negatives can vary across application domains. The receiving operating characteristic (ROC) curve provides a visual representation of the trade‐off between these two types of errors. Because the SVM does not produce a predicted probability, an ROC curve cannot be constructed in the traditional way of thresholding a predicted probability. However, a sequence of weighted SVMs can be used to construct an ROC curve. Although ROC curves constructed using weighted SVMs have great potential for allowing ROC curves analyses that cannot be done by thresholding predicted probabilities, their theoretical properties have heretofore been underdeveloped. We propose a method for constructing confidence bands for the SVM ROC curve and provide the theoretical justification for the SVM ROC curve by showing that the risk function of the estimated decision rule is uniformly consistent across the weight parameter. We demonstrate the proposed confidence band method using simulation studies. We present a predictive model for treatment response in breast cancer as an illustrative example. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

174. Seroepidemiology of Hepatitis B in the Democratic Republic of the Congo

Author

Thompson, Peyton, primary, Parr, Jonathan B., additional, Holzmayer, Vera, additional, Carrel, Margaret, additional, Tshefu, Antoinette, additional, Mwandagalirwa, Kashamuka, additional, Muwonga, Jérémie, additional, Welo, Placide O., additional, Fwamba, Franck, additional, Kuhns, Mary, additional, Jhaveri, Ravi, additional, Meshnick, Steven R., additional, and Cloherty, Gavin, additional

Published
2019
Full Text
View/download PDF

176. Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost.

Author

Perfect, Chase and Jhaveri, Ravi

Subjects
*MIDDLE-income countries, *SERIAL publications, *HEPATITIS C, *WORLD health, *MEDICAL screening, *ANTIVIRAL agents, *MEDICAL care costs, *LOW-income countries
Abstract

Over the last decade, Hepatitis C virus has persisted and evolved as a domestic and global health challenge for adults and children. The challenges involve both increased cases in the United States and cost of treatment both in the US and globally. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

190. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium

Author

Degré, Delphine, Sersté, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Vanwolleghem, Thomas, Negrin Dastis, Sergio, Gustot, Thierry, Geerts, Anja, Van Steenkiste, Christophe, de Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, Jhaveri, Ravi, Liver Cell Biology, Laboratory of Molecullar and Cellular Therapy, Basic (bio-) Medical Sciences, Gastroenterology & Hepatology, Jhaveri, Ravi, UCL - (SLuc) Service de gastro-entérologie, and UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie

Subjects
Male, Simeprevir, Cirrhosis, Psychologie appliquée, Hepacivirus, Biochemistry, Gastroenterology, 0302 clinical medicine, Belgium, Animal Cells, Ethnicities, Medicine, lcsh:Science, Aged, 80 and over, Liver Diseases, Sciences bio-médicales et agricoles, Blood, Drug Therapy, Combination, 030211 gastroenterology & hepatology, Cellular Types, Biologie, Viral load, medicine.medical_specialty, Genotype, Gastroenterology and Hepatology, Antiviral Agents, Microbiology, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Albumins, Humans, Adverse effect, Aged, Blood Cells, Flaviviruses, lcsh:R, Organisms, Biology and Life Sciences, Proteins, medicine.disease, chemistry, Immunology, lcsh:Q, Population Groupings, Human medicine, Developmental Biology, Africans, Liver Cirrhosis, RNA viruses, Sofosbuvir, Physiology, lcsh:Medicine, medicine.disease_cause, Cohort Studies, chemistry.chemical_compound, Medicine and Health Sciences, 030212 general & internal medicine, Pathology and laboratory medicine, Medicine(all), Multidisciplinary, Agricultural and Biological Sciences(all), Hepatitis C virus, Hematology, Hepatitis C, Middle Aged, Medical microbiology, Viral Load, Body Fluids, Treatment Outcome, Viruses, RNA, Viral, Female, Pathogens, Anatomy, Engineering sciences. Technology, Research Article, medicine.drug, Adult, Platelets, Virology, Internal medicine, Ribavirin, Biochemistry, Genetics and Molecular Biology(all), business.industry, Viral pathogens, Cell Biology, Hepatitis C, Chronic, Fibrosis, Hepatitis viruses, Microbial pathogens, People and Places, Interferons, business, Viral Transmission and Infection
Abstract

Introduction: Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods: Eighty-seven GT4 treatment-naïve or -Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Results: Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received RBV treatment. The overall sustained virologic response at least 12 weeks after treatment (SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9% and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7% (p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrhosis and severe disease. The treatment was well tolerated and no patient died or discontinued treatment due to adverse events. Conclusions: Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase the rate of SVR12., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017
Full Text
View/download PDF

191. Myths and Misconceptions: Varicella-Zoster Virus Exposure, Infection Risks, Complications, and Treatments.

Author

Newman, Alexander M. and Jhaveri, Ravi

Abstract

Varicella zoster and herpes zoster are infections caused by the highly contagious varicella-zoster virus (VZV). Despite widespread availability of vaccines against VZV, as well as varicella vaccination rates >95%, VZV remains a public health concern because of several common myths and misconceptions. Because of the success of routine varicella vaccination programs, some people mistakenly believe that varicella and herpes zoster are now no longer a threat to public health. Another common misconception is that shingles is less infectious than varicella; however, clinical evidence indicates otherwise. Several knowledge gaps exist around VZV transmission and the availability and use of varicella zoster immune globulin (human) for postexposure prophylaxis against VZV. To help reduce the incidence of severe disease in high-risk individuals (eg, elderly people, pregnant women, unvaccinated persons, infants, and immunocompromised children and adults), this article addresses misbeliefs and broadens awareness of VZV exposure, infection risks, complications, and treatments. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

192. Update on Associated Risk Factors, Diagnosis, and Management of Recurrent Urinary Tract Infections in Children.

Author

Khan, Anum, Jhaveri, Ravi, Seed, Patrick C, and Arshad, Mehreen

Subjects
*URINARY tract infection diagnosis, *URINARY tract infection prevention, *URINARY tract infections, *URINARY tract infection treatment, *ALTERNATIVE medicine, *DRUG resistance in microorganisms, *DISEASE relapse, *CHILDREN, *DISEASE risk factors
Abstract

Recurrent urinary tract infection (rUTI) continues to challenge pediatric care providers. The diagnosis of an rUTI can be difficult, especially in young febrile children. Antibiotic resistance rates continue to rise, which limits oral treatment options. Prophylactic antibiotics are used commonly to manage rUTI, but their use increases the risk of rUTI with antibiotic-resistant strains without significantly reducing renal scarring. Alternative therapies for rUTI include probiotics and anthocyanidins (eg, cranberry extract) to reduce gut colonization by uropathogens and prevent bacterial adhesion to uroepithelia, but efficacy data for these treatments are sparse. The future of rUTI care rests in addressing the following contemporary issues: best diagnostic practices, risk factors associated with rUTI, and the prevention of recurrent infection. In this review, we summarize the state of the art for each of these issues and highlight future studies that will aim to take an alternative approach to managing rUTI. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

193. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.

Author

Nguyen, Joehl, Barritt IV, A. Sidney, Jhaveri, Ravi, and Barritt, A Sidney 4th

Abstract

Objective: To evaluate the cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with chronic hepatitis C virus (HCV) infection compared with treatment deferral.Study Design: We constructed a Markov model to assess the cost effectiveness of treating a hypothetical cohort of 30 000 adolescent patients with chronic HCV at age 12 years compared with deferring treatment until adulthood from a societal perspective. Model inputs for transition probabilities, HCV treatment and medical care costs, and quality-adjusted life-year (QALY) utilities were derived from the literature and wholesale acquisition estimates. Deterministic sensitivity analyses varied parameters for non-HCV medical care and treatment cost, reinfection rates, treatment uptake, disease progression, liver transplant survival, and treatment with recently approved pangenotypic direct-acting antiviral agents. Discounted costs and total QALYs per person were quantified after 30 years. Cost effectiveness was evaluated as the incremental change in total medical costs per QALY gained.Results: The incremental cost effectiveness of early treatment initiation compared with deferred treatment was approximately $27 000 per QALY gained after 30 years and considered cost effective. In a scenario analysis, hypothetical treatment initiation with currently available pangenotypic agents would be even more cost effective, ranging from $10 000 to $21 000 per QALY gained. Cost-effectiveness estimates were sensitive to variations in decompensated cirrhosis progression in adolescence, adult reinfection, and treatment uptake in adults.Conclusions: Early treatment in adolescent patients with chronic HCV infection with currently available direct-acting antivirals seems to be cost effective compared with deferred treatment. Future efforts to control the HCV epidemic should include increasing the number of children treated. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

194. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium

Author

UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Degré, Delphine, Sersté, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Vanwolleghem, Thomas, Negrin Dastis, Sergio, Gustot, Thierry, Geerts, Anja, Van Steenkiste, Christophe, de Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, Jhaveri, Ravi, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Degré, Delphine, Sersté, Thomas, Lasser, Luc, Delwaide, Jean, Starkel, Peter, Laleman, Wim, Langlet, Philippe, Reynaert, Hendrik, Bourgeois, Stefan, Vanwolleghem, Thomas, Negrin Dastis, Sergio, Gustot, Thierry, Geerts, Anja, Van Steenkiste, Christophe, de Galocsy, Chantal, Lepida, Antonia, Orlent, Hans, Moreno, Christophe, and Jhaveri, Ravi

Abstract

Introduction Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens. Most trials have been conducted in HCV genotype (GT) 1 and data for interferon-free regimens in GT4 patients are limited. The aim of this study was to evaluate the safety and efficacy of sofosbuvir plus simeprevir in a real-world cohort of HCV GT4 patients with advanced fibrosis. Patients and Methods Eighty-seven GT4 treatment-naïve or –Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Results Patients were 51.7% male, 78.2% IFN/RBV treatment-experienced, and 37.9% received RBV treatment. The overall sustained virologic response at least 12 weeks after treatment (SVR12) rate was 87.4% while patients treated with and without RBV had rates of 87.9% and 87% (p = 0.593), respectively, and patients with advanced fibrosis (F3) and patients with cirrhosis had SVR12 rates of 94.4% and 82.4% (p = 0.087), respectively. SVR12 rates in treatment-naïve patients and in IFN/RBV -experienced patients were 78.9% and 89.7% (p = 0.191), respectively. Treatment failure occurred most commonly in patients with cirrhosis and severe disease. The treatment was well tolerated and no patient died or discontinued treatment due to adverse events. Conclusions Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated. RBV did not appear to increase the rate of SVR12.

Published
2017

198. The Impact of Respiratory Viral Testing in Hospitalized Adult Patients at a Tertiary Care Facility

Author

Ciccone, Emily, Chundi, Vahini, Miller, Melissa, DiBiase, Lauren, Weber, David, Juliano, Jonathan, Jhaveri, Ravi, and Willis, Zachary

Subjects
Abstracts, Poster Abstract
Abstract

Background The use of multiplex nucleic acid amplification assays to detect respiratory viruses is increasing. However, these tests are expensive, and the clinical significance of a positive result is often unclear. Positive viral results have the potential to decrease antibiotic use and length of stay, but their actual impact is unknown. Methods We completed a retrospective review of all adult patients with positive respiratory viral panel (RVP; GenMark) and/or rapid RSV/influenza PCR tests (Cepheid Xpert) collected within 48 hours of admission to the general inpatient or stepdown units of an academic tertiary care hospital between September 1, 2015 and March 15, 2016. Data collected included demographics, comorbidities, clinical presentation, time of test collection and result, additional diagnostic evaluation, and antibiotic use. Results A total of 221 positive respiratory viral tests were collected on 215 patients during the study period. The median age at time of testing was 56.8 years; 48% were female. Respiratory symptoms were documented in 92.8% of cases. COPD was the most common respiratory co-morbidity (20.2%), while 30% of patients had cancer, and 3.2% were HIV-infected. Respiratory support on admission was common (51.6%). A rapid PCR and RVP were performed in 58.8% of cases, while 28.5% had only an RVP and 12.7% had only a rapid PCR. Of the patients who had a positive rapid PCR, 17.6% also had an RVP done. Antibiotics were started within 24 hours of presentation in 87.4% of all cases and 70.6% of patients who had a positive rapid PCR. Rhinovirus was the most frequently isolated pathogen (44.6% of positive tests) followed by metapneumovirus (14%), respiratory syncytial virus (13.5%), and coronavirus (13.5%). Median time from specimen collection to result was 38.8 hours for RVP, and 15.3% were resulted after patient discharge. For those who had a rapid PCR alone, median time from collection to result was 1.5 hours. Conclusion In this non-critically ill cohort, most patients with positive viral assays received antibiotics, and a substantial number of RVPs were resulted after discharge. This suggests that there are many lost opportunities to impact clinical management with respiratory viral testing. Disclosures M. Miller, GenMark Diagnostics: Grant Investigator, Research support and Salary; R. Jhaveri, GenMark: Investigator, Grant recipient

Published
2017

200. Contributors

Author

Aaskov, John, Adachi, Kristina, Aebi, Christoph, Alexander, Kenneth A., Al-Rawahi, Ghada N., Al-Zubeidi, Duha, Anjum, Seher, Ardura, Monica I., Arnon, Stephen S., Arrington, Amy, Arvin, Ann M., Atmar, Robert L., Baker, Amira, Baker, Carol J., Baltimore, Robert S., Barenkamp, Stephen J., Barnett, Elizabeth D., Barton, Theresa, Benard, Gil, Bender, Jeffrey M., Berry, Gregory J., Bhatt, Amit, Bluestone, Charles D., Blumer, Jeffrey L., Bocchini, Claire, Boyer, Kenneth M., Bradley, John S., Brasil, Patricia, Britt, William J., Bronstein, David E., Bruckner, David A., Bryant, Kristina A., Buckingham, Steven C., Byington, Carrie L., Cabada, Miguel M., Cadilla, Adriana, Campbell, Judith R., Caron, Justin E., Carrillo-Marquez, Maria, Casey, Janet R., Castagnini, Luis A., Chacko, Mariam R., Chandramohan, Lakshmi, Chapman, Louisa E., Charrel, Remi N., Chea-Woo, Elsa, Cheifetz, Ira M., Chen, Tempe K., Cherry, James D., Chinen, Javier, Ching, Natascha, Chinn, Ivan K., Christenson, John C., Coffin, Susan E., Correa, Armando G., Cox, Elaine G., Crews, Jonathan D., Cruz, Andrea T., Davidovics, Zev, Dehority, Walter N., de Lamballerie, Xavier, Dennehy, Penelope H., Doan, Minh L., Dobson, Simon R., Drutz, Jan E., Dubray, Kara A., Duppenthaler, Andrea, Dvorak, Christopher C., Edelstein, Paul H., Edwards, Kathryn M., Edwards, Morven S., El-Kamary, Samer S., Englund, Janet A., Ericson, Jessica, Fan, Leland L., Federman, Myke, Fernando, Pedro, Fischer, Philip R., Fisher, Brian T., Fisher, Randall G., Fishman, Douglas S., Flores, Anthony R., Foster, Catherine, Friedman, Ellen M., Gabaglia, Claudia Raja, Garcia, Lynne S., Gauthier, Gregory M., Gershon, Anne A., Gigliotti, Francis, Gilger, Mark A., Gillespie, Susan L., Glaser, Carol A., Goldman, David L., Goldman, Jennifer L., Goldstein, Nira A., Gonzalez, Blanca E., Green, Michael D., Groll, Andreas, Grose, Charles, Gubler, Duane J., Guevara, Javier Nieto, Hall, Caroline B., Hall, Roy A., Halstead, Scott B., Hamano, Shinjiro, Hammerschlag, Margaret R., Hannemann, Nicole L., Hanson, I. Celine, Harik, Nada, Harriman, Kathleen H., Harrison, Gail J., Healy, C. Mary, Heininger, Ulrich, Hemming-Harlo, Maria, Henderson, Sheryl L., Heresi, Gloria P., Hiatt, Peter W., Hill, Harry R., Hilmers, David C., Hoffman, Jill A., Hotez, Peter J., Howard, Leigh M., Hulten, Kristina G., Humphries, Romney M., Hunstad, David A., Hunt, W. Garrett, Huskins, W. Charles, Hyun, David Y., Jackson, Mary Anne, Jacobs, Michael R., Jacobs, Richard F., Jhaveri, Ravi, Odom, Audrey R., Johnston, Samantha H., Julapalli, Meena R., Kaplan, Sheldon L., Kearns, Gregory L., Khouri, Jessica M., Kim, Kwang Sik, Kim, Yae-Jean, King, Katherine Y., Kirchhoff, Louis V., Kleiman, Martin B., Klein, Bruce S., Kohlhoff, Stephan A., Kollmann, Tobias R., Korpe, Poonum S., Kosek, Margaret, Koster, Michael P., Krause, Peter J., Krilov, Leonard R., Krogstad, Paul, Krysan, Damian J., Kuan, Edward, Kuhls, Thomas, Labuda, Sarah M., Lantos, Paul M., La Pine, Timothy R., Heinimäki, Suvi, Larkin, Jerome M., Laurens, Matthew B., Leach, Charles T., Leber, Amy, Leggiadro, Robert J., Lehman, Deborah, Lennon, Diana R., Leung, Daniel H., Levy, Moise L., Linam, W. Matthew, Logan, Latania K., Lotze, Timothy E., Lucero, Yalda C., Lugo, Debra J., Luk, Berkley, Maloney, Susan A., Mann, Michelle C., Marquez, Lucila, Martin, Kimberly C., Mascola, Laurene, Mason, Edward O., Jr, Maspons, Aldo, Mazade, Marc A., McBride, Holly E., McCullers, Jonathan A., McIntosh, Kenneth, McJunkin, James E., McKee, Kelly T., Jr, McKinney, Ross, Jr, McNeil, J. Chase, Mejia, Rojelio, Mejias, Asuncion, Mendes Giannini, Maria José Soares, Michaels, Marian G., Michelow, Ian C., Miller, Marjorie J., Mills, James N., Mithal, Leena B., Moffett, Kathryn S., Montes, Martin, Muller, Martha, Mungwira, Randy George, Murphy, James R., Nadipuram, Santhosh M., Nataro, James P., Needham, Heather, Nielsen-Saines, Karin, Nieves, Delma J., Oberhelman, Richard, Ochoa, Theresa J., Olivero, Rosemary M., O'Ryan, Miguel, Overturf, Gary D., Palazzi, Debra L., Pannaraj, Pia S., Patel, Janak A., Paul, Mary E., Pelton, Stephen I., Pence, Morgan A., Perfect, John R., Peters, C.J., Petri, William A., Jr, Pham, Yen H., Pinheiro, Francisco P., Pinsky, Benjamin A., Pong, Alice, Porsch, Eric A., Purcell, Joan S., Quanquin, Natalie M., Quinn, Kevin K., Abdel-Rahman, Susan M., Ramilo, Octavio, Ramraj, Ramya, Revell, Paula A., Rimoin, Anne W., Romero, José R., Ross, Lawrence, Rowley, Anne H., Rupprecht, Charles E., Saez-Llorens, Xavier, Sammons, Julia Shaklee, Sánchez, Pablo, Sande, Linette, Santisteban-Ponce, Javier, Sass, Laura A., Scholand, Stephen J., Schulte, Danica J., Schuster, Jennifer E., Schutze, Gordon E., Seed, Patrick C., Serpa, Jose A., Shah, Samir S., Shapiro, Eugene D., Shapiro, Nina L., Shearer, William T., Shimizu-Cohen, Robyn, Shulman, Stanford T., Shehab, Kareem W., Shehab, Ziad M., Simos, Constantine, Smit, Michael A., Smith, P. Brian, Soni, Priya R., Sood, Sunil K., Staat, Mary Allen, Stark, Damien, Starke, Jeffrey R., Statler, Victoria A., Stechenberg, Barbara W., Steinbach, William J., St. Geme, Joseph W., III, Suen, Jeffrey, Sung, Lillian, Swanson, Douglas S., Tan, Tina Q., Taylor, Ruston S., Tolle, Michael A., Toltzis, Philip, Tomko, Stuart R., Tosi, Michael F., Tovar Padua, Leidy J., Travassos da Rosa, Amelia P.A., Tsai, Theodore F., Vahabzadeh-Hagh, Andrew M., Velarde, Jorge J., Vallejo, Jesus G., Vanchiere, John A., Venick, Robert S., Verma, Sanjay, Versalovic, James, Vesikari, Timo, Wald, Ellen R., Walsh, Thomas J., Ward, Mark A., Wattier, Rachel L., Way, Sing Sing, Weatherhead, Jill, Weinberg, Michelle, Weinberg, Nicholas, Wellington, Melanie, Welliver, Robert C., Sr, Wheeler, J. Gary, White, A. Clinton, Jr, Whitworth, Suzanne, Wiedermann, Bernhard L., Williams, John V., Williams-Bouyer, Natalie M., Woods, Charles R., Jr, Wright, Terry W., Yeganeh, Nave, Young, Edward J., Zakhour, Ramia, and Zaoutis, Theoklis

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results